Drugs / levonorgestrel butanoate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04143659 | Mar 2020 → Mar 2026 overdue | — | Premier Research | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02173808 | May 2011 → Jun 2012 | — | Premier Research | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07222228 | Apr 2026 → Dec 2028 expected | — | Premier Research | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levonorgestrel butanoate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02173808 ↗ |
| Route | Intramuscular | “LB administered as an IM or SQ injection” NCT04143659 ↗ |
| Route | Subcutaneous | “LB administered as an IM or SQ injection” NCT04143659 ↗ |